Mozaffari, E. et al: Immunocompromised patients hospitalized for COVID-19 in the United States: evolving patient characteristics and clinical outcomes across emerging variants

Zurück zur Übersicht

15.-18.04.2023 / ECCMID

Studiensammlung zu COVID-19

Santos, J. R. et al: The REDPINE Study: Efficacy and Safety of Remdesivir in People With Moderately and Severely Reduced Kidney Function Hospitalised for COVID-19 Pneumonia

15.-18.04.2023 / ECCMID

Lee, E. et al: Remdesivir Reduces Readmission in Immunocompromised Adult Patients Hospitalised With COVID 19

15.-18.04.2023 / ECCMID

Mozaffari, E. et al: Remdesivir is associated with decreased mortality in hospitalised COVID-19 patients requiring high-flow oxygen in the United States

15.-18.04.2023 / ECCMID

Mozaffari, E. et al: Remdesivir is associated with lower mortality in cancer patients hospitalized for COVID-19 across emerging variants

15.-18.04.2023 / ECCMID

Gupta, R. S. et al: Remdesivir Reduced the Hazard of Hospital Readmission in People With COVID-19 Admitted to the ICU While Delta and Omicron Were de Predominant Circulation Variants

15.-18.04.2023 / ECCMID

Mozaffari, E. et al: Remdesivir reduces mortality in hospitalized COVID 19 patients across variant eras

19.-22.02.2023 / CROI

Mozaffari, E. et al: Remdesivir reduces mortality in immunocompromised patients hospitalized vor COVID 19

19.-22.02.2023 / CROI

Mozaffari, E. et al: Remdesivir is associated with reduced readmission after COVID 19 hospitalization

19.-22.02.2023 / CROI

Humeniuk R. et al.: Pharmacokinetics Inform Remdesivir Dosing for Patients With Severe Renal Impairment

19.-22.02.2023 / CROI

Ahmed, A. et al: Remdesivir Treatment for COVID-19 in Hospitalized Children: CARAVAN Interim Results

12.-16.02.2022 / CROI